Dylan (on behalf of Laura Chico)'s questions to Xenon Pharmaceuticals Inc (XENE) leadership • Q3 2024
Question
Dylan, on behalf of Laura Chico, asked about the expected cadence of data readouts from the broader early-stage ion channel portfolio and whether any data should be anticipated in 2025.
Answer
CEO Ian Mortimer stated that specific timelines have not yet been provided. He reiterated that the next-generation Kv7 and Nav1.7 programs are in IND-enabling studies and are expected to enter the clinic in 2025. Once first-in-human studies are underway, the company will have a better sense of human PK and can provide more detailed timelines for subsequent data readouts.